{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:03:47Z","timestamp":1789891427513,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":1489,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1111\/j.1469-0691.2010.03155.x","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T23:11:54Z","timestamp":1275952314000},"page":"1649-1655","source":"Crossref","is-referenced-by-count":100,"title":["In-Vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years"],"prefix":"10.1016","volume":"16","author":[{"given":"R.","family":"Krausse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2010.03155.x_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jac\/dkn158","article-title":"Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece","volume":"62","author":"Kechagia","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib2","first-page":"112","article-title":"Isolation of mycoplasmas and Chlamydia trachomatis from patients with genitourinary tract infections","volume":"15","author":"Krausse","year":"1987","journal-title":"Immun Infekt"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/CMR.18.4.757-789.2005","article-title":"Mycoplasmas and ureaplasmas as neonatal pathogens","volume":"18","author":"Waites","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.siny.2008.11.009","article-title":"Congenital and opportunistic infections: Ureaplasma species and Mycoplasma hominis","volume":"14","author":"Waites","year":"2009","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib6","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/AAC.47.10.3323-3325.2003","article-title":"DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones","volume":"47","author":"B\u00e9b\u00e9ar","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib7","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.45.9.2604-2608.2001","volume":"45","author":"Kenny","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01962178","article-title":"Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis","volume":"7","author":"Krausse","year":"1988","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.42.5.1290","article-title":"Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents","volume":"42","author":"Matlow","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl S1","key":"10.1111\/j.1469-0691.2010.03155.x_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/clinids\/17.Supplement_1.S200","article-title":"Susceptibility of mycoplasmas to antimicrobial agents: Clinical Implications","volume":"17","author":"McCormack","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jac\/40.5.622","article-title":"Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections","volume":"40","author":"Taylor-Robinson","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/AAC.47.1.161-165.2003","article-title":"In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib13","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1128\/AAC.34.12.2297","article-title":"Increase in resistance of Mycoplasma hominis to tetracycline","volume":"34","author":"Cummings","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1128\/AAC.00960-07","article-title":"Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracyclines","volume":"52","author":"D\u00e9grange","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib15","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1128\/AAC.45.10.2958-2960.2001","article-title":"Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of Mycoplasma hominis","volume":"45","author":"Furneri","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijantimicag.2006.09.008","article-title":"Characterisation of in vitro-selected mutants of Ureaplasma parvum resistant to macrolides and related antibiotics","volume":"29","author":"Pereyre","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.4049\/jimmunol.92.6.958","article-title":"Mycoplasma species identification based upon growth inhibition by specific antisera","volume":"92","author":"Clyde","year":"1964","journal-title":"J Immunol"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/jcm.3.6.613-625.1976","article-title":"Differential agar medium (A7) for identification of Ureaplasma urealyticum (human T mycoplasmas) in primary cultures of clinical material","volume":"3","author":"Shepard","year":"1976","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib20","series-title":"Performance standards for antimicrobial susceptibility testing. 17th informational supplement, document M100-S17","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib21","first-page":"36","article-title":"Prevalence and antibiotic susceptibility of genital Mycoplasma hominis and Ureaplasma urealyticum in a university hospital in Turkey","volume":"33","author":"Karabay","year":"2006","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.diagmicrobio.2003.10.004","article-title":"Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method","volume":"48","author":"Ngan","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0732-8893(02)00459-5","article-title":"In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides","volume":"44","author":"Samra","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib24","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.48.8.3165-3168.2004","article-title":"In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas","volume":"48","author":"Pereyre","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl","key":"10.1111\/j.1469-0691.2010.03155.x_bib25","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/jac\/45.suppl_3.29","article-title":"Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp","volume":"45","author":"Duffy","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib26","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1128\/AAC.44.7.1980-1982.2000","article-title":"Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas","volume":"44","author":"B\u00e9b\u00e9ar","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/00365540110026782","article-title":"Occurrence and antimicrobial susceptibility of Ureaplasma parvum (Ureaplasma urealyticum Biovar 1) and Ureaplasma urealyticum (Ureaplasma urealyticum Biovar 2) from patients with adverse preganancy outcomes and normal pregnant women","volume":"33","author":"Mart\u00ednez","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10096-008-0687-z","article-title":"Detection of Ureaplasma biovars and polymerase chain reaction-based subtyping of Ureaplasma parvum in women with or without symptoms of genital infections","volume":"28","author":"De Francesco","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib29","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.44.9.2557-2560.2000","article-title":"In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized","volume":"44","author":"B\u00e9b\u00e9ar","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1051\/vetres:2000100","article-title":"Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species","volume":"31","author":"Hannan","year":"2000","journal-title":"Vet Res"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/dkl026","article-title":"Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin","volume":"57","author":"Pereyre","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03155.x_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bpobgyn.2007.01.011","article-title":"The role of mycoplasmas in pregnancy outcome","volume":"21","author":"Taylor-Robinson","year":"2007","journal-title":"Best Pract Res Clin Obstet Gynaecol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14605590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14605590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:13:30Z","timestamp":1685625210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14605590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":30,"aliases":["10.1111\/j.1469-0691.2009.03155.x"],"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1198743X14605590"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03155.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}